Free shipping on all orders over $ 500

KSQ-4279

Cat. No. M11443

All AbMole products are for research use only, cannot be used for human consumption.

KSQ-4279 Structure
Synonym:

USP1-IN-1

Size Price Availability Quantity
1mg USD 180 In stock
5mg USD 450 In stock
10mg USD 680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

USP1-IN-1 (USP1-IN-1, Formula I) is a first-in-class, selective allosteric USP1 small molecule inhibitor used in oncology research alone or in combination with PARP inhibition.

Chemical Information
Molecular Weight 534.54
Formula C27H25F3N8O
CAS Number 2446480-97-1
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Related PARP Products
ABT-888

ABT-888 (Veliparib) is a potent inhibitor of PARP-1 and PARP-2 with Ki values of 5.2nM and 2.9nM respectively.

AG-014699 phosphate

AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM.

AG14361

AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM.

AZD2281 (Olaparib)

AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator.

Talazoparib

Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: KSQ-4279, USP1-IN-1 supplier, PARP, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.